Association of Obstructive Sleep Apnea with Post-Acute Sequelae of SARS-CoV-2 infection (PASC)
Background: Obstructive sleep apnea (OSA) is associated with COVID-19 infection. Fewer investigations have assessed OSA as a possible risk for the development of Post-Acute Sequelae of SARS-CoV-2 infection (PASC).
Research Question: In a general population, is OSA associated with increased odds of PASC-related symptoms and with an overall definition of PASC?.
Study Design: Cross-sectional survey of a general population of 24,803 U.S. adults.
Results: COVID-19 infection occurred in 10,324 (41.6%) participants. Prevalence rates for a wide variety of persistent (> 3 months post infection) putative PASC-related physical and mental health symptoms ranged from 6.5% (peripheral edema) to 19.6% (nervous/anxious). In logistic regression models adjusted for demographic, anthropometric, comorbid medical and socioeconomic factors, OSA was associated with all putative PASC-related symptoms with the highest adjusted odds ratios (aOR) being fever (2.053) and nervous/anxious (1.939) respectively. Elastic net regression identified the 13 of 37 symptoms most strongly associated with COVID-19 infection. Four definitions of PASC were developed using these symptoms either weighted equally or proportionally by their regression coefficients. In all 4 logistic regression models using these definitions, OSA was associated with PASC (range of aORs: 1.934-2.071); this association was mitigated in those with treated OSA. In the best fitting overall model requiring ≥3 symptoms, PASC prevalence was 21.9%.
Conclusion: In a general population sample, OSA is associated with the development of PASC-related symptoms and a global definition of PASC. A PASC definition requiring the presence of 3 or more symptoms may be useful in identifying cases and for future research.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2023 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2023) vom: 31. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quan, Stuart F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 23.03.2024 published: Electronic UpdateIn: Am J Med. 2024 Feb 22;:. - PMID 38401674 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2023.12.30.23300666 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367253674 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367253674 | ||
| 003 | DE-627 | ||
| 005 | 20240324234946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.30.23300666 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM367253674 | ||
| 035 | |a (NLM)38234859 | ||
| 035 | |a (PII)2023.12.30.23300666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quan, Stuart F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association of Obstructive Sleep Apnea with Post-Acute Sequelae of SARS-CoV-2 infection (PASC) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Am J Med. 2024 Feb 22;:. - PMID 38401674 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Background: Obstructive sleep apnea (OSA) is associated with COVID-19 infection. Fewer investigations have assessed OSA as a possible risk for the development of Post-Acute Sequelae of SARS-CoV-2 infection (PASC) | ||
| 520 | |a Research Question: In a general population, is OSA associated with increased odds of PASC-related symptoms and with an overall definition of PASC? | ||
| 520 | |a Study Design: Cross-sectional survey of a general population of 24,803 U.S. adults | ||
| 520 | |a Results: COVID-19 infection occurred in 10,324 (41.6%) participants. Prevalence rates for a wide variety of persistent (> 3 months post infection) putative PASC-related physical and mental health symptoms ranged from 6.5% (peripheral edema) to 19.6% (nervous/anxious). In logistic regression models adjusted for demographic, anthropometric, comorbid medical and socioeconomic factors, OSA was associated with all putative PASC-related symptoms with the highest adjusted odds ratios (aOR) being fever (2.053) and nervous/anxious (1.939) respectively. Elastic net regression identified the 13 of 37 symptoms most strongly associated with COVID-19 infection. Four definitions of PASC were developed using these symptoms either weighted equally or proportionally by their regression coefficients. In all 4 logistic regression models using these definitions, OSA was associated with PASC (range of aORs: 1.934-2.071); this association was mitigated in those with treated OSA. In the best fitting overall model requiring ≥3 symptoms, PASC prevalence was 21.9% | ||
| 520 | |a Conclusion: In a general population sample, OSA is associated with the development of PASC-related symptoms and a global definition of PASC. A PASC definition requiring the presence of 3 or more symptoms may be useful in identifying cases and for future research | ||
| 650 | 4 | |a Preprint | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Long COVID | |
| 650 | 4 | |a Obstructive Sleep Apnea | |
| 650 | 4 | |a PASC | |
| 650 | 4 | |a Post-Acute Sequelae of SARS-CoV-2 infection | |
| 700 | 1 | |a Weaver, Matthew D |e verfasserin |4 aut | |
| 700 | 1 | |a Czeisler, Mark É |e verfasserin |4 aut | |
| 700 | 1 | |a Barger, Laura K |e verfasserin |4 aut | |
| 700 | 1 | |a Booker, Lauren A |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Mark E |e verfasserin |4 aut | |
| 700 | 1 | |a Jackson, Melinda L |e verfasserin |4 aut | |
| 700 | 1 | |a Lane, Rashon I |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, Christine F |e verfasserin |4 aut | |
| 700 | 1 | |a Ridgers, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Robbins, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Varma, Prerna |e verfasserin |4 aut | |
| 700 | 1 | |a Wiley, Joshua F |e verfasserin |4 aut | |
| 700 | 1 | |a Rajaratnam, Shantha M W |e verfasserin |4 aut | |
| 700 | 1 | |a Czeisler, Charles A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2023) vom: 31. Dez. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2023 |g day:31 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.30.23300666 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 31 |c 12 | ||